Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2020, with a specific reporting date of July 13, 2020. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs).
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of shares via dividend reinvestment within an Individual Savings Account (ISA).
- Transaction Date: July 10, 2020.
- Transaction Price: £15.9271 per share.
- Volumes: 25 shares acquired by Mr. D. Redfern (Chief Strategy Officer) and 21 shares acquired by Ms. V. Whyte (Company Secretary).
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents routine compliance notifications for insider share acquisitions resulting from dividend reinvestment plans.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is a statutory disclosure of specific shareholding changes.
Key Facts for Investor Verification
- Verify the share price of £15.9271 against the market price on July 10, 2020, to confirm the execution price of the dividend reinvestment.
- Confirm that the transactions were executed within an ISA wrapper, as stated, which may have tax implications for the individuals but not the company.
- Note that the volume of shares acquired (25 and 21 shares) is nominal and does not indicate a significant change in insider ownership percentages.
- Recognize that this filing provides no data on GSK's broader financial performance for the period.